Search Results
58 Results Found for “device closure, ”
Immediate 14-day ambulatory ECG monitoring did not significantly reduce recurrent syncope at 1 year in the ASPIRED trial, but it more than doubled the detection of clinically significant arrhythmias and enabled earlier diagnosis and treatment. Following the presentation, Prof. Matthew Reed, from the Usher Institute, University of Edinburgh, and the Emergency Medicine Research Group Edinburgh, spoke about the origins of ASPIRED, the importance of earlier investigation for patients with syncope, and how this approach might be incorporated into routine care.
Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.
Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.
Prof. George Stergiou discusses wearable, cuffless and screening technologies for blood pressure measurement, where they may add value, and why accuracy remains critical for clinical decision-making.
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Day 2 hotline data at EuroPCR 2026 highlighted improved outcomes with FFR-guided PCI in TAVI, comparable 10-year survival with PCI and CABG in left main disease and consistent LAAC benefits across age groups.
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
From EHRA 2026, Dr Salik Ur Rehman discusses advances in pulsed field ablation, mapping technologies, and conduction system pacing highlight a rapidly evolving landscape in electrophysiology care.
As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchCARDIO. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the cardiology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year.
Long-term results from the DanGer Shock trial confirm that early mechanical circulatory support can improve survival in STEMI-related cardiogenic shock. Professor Peter Clemmensen highlights the need to individualise treatment, particularly in elderly patients, and calls for greater emphasis on prevention and global cardiovascular health to ensure advances translate across diverse healthcare settings.
Cardiac implantable electronic devices are undergoing rapid change, with conduction system pacing and new strategies for resynchronization therapy challenging long-standing standards. At ESC 2025, Dr Haran Burri highlights late-breaking trial data that could redefine best practice and underscores the importance of careful technique and training to translate these advances into meaningful patient benefit.
Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
